Observational Assessment of Safety in Seroquel (OASIS)
The OASIS study is designed to examine the short-term (up to 12 weeks) safety and use of quetiapine fumarate in an prolonged-release formulation (Seroquel XL™), along with a comparator group started on the immediate-release formulation, quetiapine IR. Any patient in England will be eligible for inclusion when a clinical decision has been made to prescribe either the XL or IR preparation as part of normal clinical practice for the clinical diagnosis of schizophrenia and mania associated with bipolar disorder. This study will enable the systematic collection and reporting of safety data on patients newly initiated on treatment with quetiapine XL. Its purpose will be to provide information on a large number of such patients and the treatment they received in a mental health care trust setting.
Further Information
Find out about the progress that's been made to date...
Observational Assessment of Safety in Seroquel XL (OASIS) Study